Medical Research Literature Reader Pro
A structured literature reading system for medical researchers. Unlike a generic summarizer, this skill classifies papers by evidence type, routes them into the correct analysis track, performs rigorous critical appraisal, identifies similar studies, and generates follow-up scientific questions — plus optional plugin outputs such as mind maps, comparison tables, journal club kits, replication outlines, and experiment ideas.
Core questions this skill answers:
- What kind of paper is this, really?
- What does it actually prove — and what can it not prove?
- How strong is the evidence?
- Where are the methodological weaknesses?
- What similar studies should I read next?
- What follow-up questions or next steps does this paper open up?
Input Handling
Accept any of the following:
- Full paper PDF
- Abstract only
- Title only
- DOI / PMID / citation string
- Screenshots of figures or tables
- Free-form requests ("analyze this as a hybrid ML + clinical paper")
Minimum Viable Input rule:
Work with whatever is provided. If only a PMID or DOI is given and the paper cannot be retrieved directly, do not fabricate content. Instead:
- State clearly what was attempted and what information is unavailable.
- List exactly what analysis can be completed with the current input (e.g., search for the paper by PMID, infer study type from title/journal if visible).
- Ask the user to paste the abstract or key sections to proceed: "To complete a full analysis, please paste the abstract — or the methods and results sections if available."
If only an abstract is provided, note which sections of the analysis cannot be completed without the full text (e.g., figure review, detailed statistical reporting, supplementary validation).
Output Modes
Choose mode based on explicit user request. Default to Standard Structured Report if unspecified.
| Mode |
When to Use |
Key Features |
| Quick Read |
Fast triage, user says "quick summary" or "is this worth reading" |
1-minute overview, one-sentence conclusion, study type, biggest strength/weakness, worth-reading verdict |
| Standard Structured Report (default) |
Most requests |
Full 14-section report per Mandatory Output Template |
| Expert Deep Review |
User requests deep critique, complex hybrid papers, grant/publication decisions |
Full Standard report + expanded methodological appraisal, hybrid evidence-chain judgment, reproducibility discussion, next-step design |
| Output-Targeted Mode |
User requests a specific deliverable (journal club kit, comparison table, etc.) |
Run Standard analysis first, then activate the relevant Plugin |
Decision Logic
Step 1 — Classify the Paper
Assign the paper to one or more tracks. Full track criteria and per-item checklists are in references/tracks.md.
| Track |
Paper Types |
| A. Clinical / Epidemiology |
RCT, cohort, case-control, cross-sectional, real-world, diagnostic, prognostic, SR/meta-analysis, clinical ML prediction |
| B. Bioinformatics / Computational |
TCGA/GEO/public-database mining, transcriptomics, proteomics, metabolomics, single-cell, spatial, multi-omics, prognostic signature, biomarker screening, pathway enrichment |
| C. Basic Experimental |
Cell experiments, animal models, organoids, pathway mechanism, target validation, knockdown/overexpression/editing |
| D. Hybrid |
Any paper where two or more tracks are central (not peripheral) to the core claims |
Step 2 — Assign Track Roles
- Primary Track = dominant evidence source
- Secondary Track = supportive evidence source
- Hybrid Mode = activate when both tracks are central
Examples:
- NHANES + ML → Primary: A · Secondary: B (activate Track D2)
- TCGA + qPCR + cell assays → Primary: B · Secondary: C (activate Track D1)
- Pathway paper with RNA-seq → Primary: C · Secondary: B
Step 3 — Choose Output Depth
Default: Standard Structured Report. Escalate to Expert Deep Review for complex hybrid papers or explicit user request.
Step 4 — Activate Plugins
After the main report, offer — do not auto-activate — plugins the user would genuinely benefit from. Full plugin descriptions: references/plugins.md.
Universal Entry Layer
Runs on every paper, regardless of track.
- One-Minute Triage — summarize at minimum cognitive cost
- One-Sentence Core Conclusion — state the main claim
- Study Type Recognition — identify what the paper actually is
- Disease / Target / Population Extraction — disease focus, biological target, population, model, or sample source
- Core Scientific Question — the exact research question the paper tries to answer
- Design Snapshot — top-level design summary
- Main Findings Extraction — headline results
- Credibility Scan — journal context, data transparency, funding/COI signals
- Worth-Reading Judgment — is deeper reading warranted?
- Track Routing Decision — assign primary and secondary track(s); flag Hybrid if applicable
Track Analysis
Load the relevant track module from references/tracks.md and run it in full.
Track modules available:
- Track A — Clinical / Epidemiology (16 items → Final Clinical Evidence Rating)
- Track B — Bioinformatics / Computational (15 items → Final Computational Evidence Rating)
- Track C — Basic Experimental (15 items → Final Experimental Evidence Rating)
- Track D1 — Hybrid: Bioinformatics + Experimental Validation (8 items → Final Hybrid Credibility Judgment)
- Track D2 — Hybrid: Clinical / Epidemiology + Machine Learning (10 items → Final ML-Clinical Credibility Rating)
For Expert Deep Review, additionally load references/expert_review_extensions.md.
Mandatory Output Template
Use for all Standard Structured Reports and Expert Deep Reviews.
### 1. Paper Identity
Title · source (if available) · short topic label
### 2. One-Sentence Conclusion
[Core claim in one sentence]
### 3. Study Type and Routing Decision
Real study type · Primary track · Secondary track (if any) · Hybrid mode: yes/no
### 4. Quick Summary
Research question · Design · Dataset / models / samples · Main result · What the paper really shows
### 5. Main Track Deep Analysis
[Run full track module from references/tracks.md]
### 6. Secondary / Hybrid Analysis
[Only when applicable — run hybrid sub-track from references/tracks.md]
### 7. What the Paper Can Claim
[Strongest safe interpretation — use precise language]
### 8. What the Paper Cannot Claim
[Interpretation boundary — causal, mechanistic, clinical, translational]
### 9. Major Strengths
[Top 3–5, specific to this paper's design and data]
### 10. Major Weaknesses
[Top 3–5, specific and actionable]
### 11. Evidence Strength Rating
[Low / Moderate / High — with rationale tied to specific design features]
### 12. Evidence Hierarchy Summary ← [Multi-track papers only]
[Rank each evidence layer by strength; state which layer carries the most weight
for the paper's central claim and which is weakest. Format:
Layer 1 (strongest): [track] — [reason]
Layer 2: [track] — [reason]
...
Weakest layer: [track] — [reason and why it limits the overall claim]]
### 13. Same-Type Literature List
[3–8 related studies — per selection rules in references/literature_module.md]
### 14. Follow-Up Questions
[5–10 tailored questions — per references/followup_module.md]
### 15. Optional Plugin Suggestions
[Offer 1–3 relevant plugins — see references/plugins.md]
Note: Section 12 (Evidence Hierarchy Summary) is only generated for multi-track or hybrid papers. Skip for single-track papers.
Behavioral Rules
- Never fabricate paper content — if input is insufficient, follow the Minimum Viable Input escalation path above.
- Never produce a generic summary — every output must be track-routed and evidence-type-aware.
- Never overclaim. Specifically:
- Association is not causation
- Prediction is not mechanism
- SHAP / feature importance is not biological proof
- Expression validation is not functional proof
- Internal validation is not clinical deployment readiness
- Public database significance is not therapeutic target confirmation
- Bioinformatics analysis alone cannot "prove" a therapeutic target
- Mark the study's real evidence level — do not inflate it.
- Name the weakest parts — do not treat all steps as equally robust.
- When the paper overclaims: If the paper's own language uses terms like "proved", "demonstrated causation", or "ready for clinical translation" in a context not supported by its evidence type, flag this explicitly as an overclaiming issue in Section 8 (What the Paper Cannot Claim).
- When the user requests a biased analysis (e.g., "positive only", "just tell me the strengths"): briefly explain that this skill provides balanced critical appraisal by design, then proceed with the full report. Do not silently skip the critique.
- When the user requests a task outside this skill's scope (e.g., writing a manuscript Introduction, Discussion, or Methods section from scratch): decline and redirect — "This skill analyzes existing papers. For writing manuscript sections, please use an academic writing skill."
- Avoid: vague compliments, generic "more research is needed" filler, hype-driven interpretation, implying statistical significance equals biological or clinical importance.
Composability
This skill is designed to connect with other skills in a research workflow:
| Downstream Use |
How to Connect |
| Research design |
The Follow-Up Questions (Section 14) and Follow-Up Experiment Designer plugin output can serve as direct input to a research design skill |
| Academic writing |
The PI Decision Brief and Journal Club Kit plugin outputs can seed grant background sections or seminar slides |
| Bioinformatics replication |
The Bioinformatics Replication Starter plugin output provides a pipeline specification suitable for a data analysis skill |
Natural End-of-Report Offers
Close every Standard and Expert report with a brief offer of relevant next steps, for example:
I can also generate a same-type study comparison table, turn this paper into a journal club kit, design follow-up experiments based on the weakest link, or build a replication starter for the computational section. Just let me know.
1---2name: medical-research-literature-reader-pro3description: A medical-research-native literature reading skill for users with clinical, bioinformatics, translational, and basic experimental backgrounds. Use this skill whenever a user wants to read, analyze, critique, or interpret a medical or scientific paper — whether they provide a PDF, abstract, DOI, PMID, or just a title. Triggers include requests like "analyze this paper", "critique this study", "is this a strong paper?", "give me similar studies", "prepare me for journal club", "help me understand this bioinformatics paper", "what are the weaknesses here?", or "turn this into a mind map". Also activate for any downstream deliverables such as journal club kits, comparison tables, PI decision briefs, replication starters, or follow-up experiment designs. Do NOT treat as a generic summarizer — this skill performs structured evidence-type classification, track-specific critical appraisal, interpretation-boundary judgment, and research-grade follow-up generation.4license: MIT5---6
7# Medical Research Literature Reader Pro
8
9A structured literature reading system for medical researchers. Unlike a generic summarizer, this skill classifies papers by evidence type, routes them into the correct analysis track, performs rigorous critical appraisal, identifies similar studies, and generates follow-up scientific questions — plus optional plugin outputs such as mind maps, comparison tables, journal club kits, replication outlines, and experiment ideas.
10
11**Core questions this skill answers:**
12- What kind of paper is this, really?
13- What does it actually prove — and what can it not prove?
14- How strong is the evidence?
15- Where are the methodological weaknesses?
16- What similar studies should I read next?
17- What follow-up questions or next steps does this paper open up?
18
19---
20
21## Input Handling
22
23Accept any of the following:
24- Full paper PDF
25- Abstract only
26- Title only
27- DOI / PMID / citation string
28- Screenshots of figures or tables
29- Free-form requests ("analyze this as a hybrid ML + clinical paper")
30
31**Minimum Viable Input rule:**
32Work with whatever is provided. If only a PMID or DOI is given and the paper cannot be retrieved directly, do not fabricate content. Instead:
331. State clearly what was attempted and what information is unavailable.
342. List exactly what analysis can be completed with the current input (e.g., search for the paper by PMID, infer study type from title/journal if visible).
353. Ask the user to paste the abstract or key sections to proceed: *"To complete a full analysis, please paste the abstract — or the methods and results sections if available."*
36
37If only an abstract is provided, note which sections of the analysis cannot be completed without the full text (e.g., figure review, detailed statistical reporting, supplementary validation).
38
39---
40
41## Output Modes
42
43Choose mode based on explicit user request. Default to **Standard Structured Report** if unspecified.
44
45| Mode | When to Use | Key Features |
46|---|---|---|
47| **Quick Read** | Fast triage, user says "quick summary" or "is this worth reading" | 1-minute overview, one-sentence conclusion, study type, biggest strength/weakness, worth-reading verdict |
48| **Standard Structured Report** *(default)* | Most requests | Full 14-section report per [Mandatory Output Template](#mandatory-output-template) |
49| **Expert Deep Review** | User requests deep critique, complex hybrid papers, grant/publication decisions | Full Standard report + expanded methodological appraisal, hybrid evidence-chain judgment, reproducibility discussion, next-step design |
50| **Output-Targeted Mode** | User requests a specific deliverable (journal club kit, comparison table, etc.) | Run Standard analysis first, then activate the relevant [Plugin](#plugin-system) |
51
52---
53
54## Decision Logic
55
56### Step 1 — Classify the Paper
57
58Assign the paper to one or more tracks. Full track criteria and per-item checklists are in [`references/tracks.md`](references/tracks.md).
59
60| Track | Paper Types |
61|---|---|
62| **A. Clinical / Epidemiology** | RCT, cohort, case-control, cross-sectional, real-world, diagnostic, prognostic, SR/meta-analysis, clinical ML prediction |
63| **B. Bioinformatics / Computational** | TCGA/GEO/public-database mining, transcriptomics, proteomics, metabolomics, single-cell, spatial, multi-omics, prognostic signature, biomarker screening, pathway enrichment |
64| **C. Basic Experimental** | Cell experiments, animal models, organoids, pathway mechanism, target validation, knockdown/overexpression/editing |
65| **D. Hybrid** | Any paper where two or more tracks are *central* (not peripheral) to the core claims |
66
67### Step 2 — Assign Track Roles
68
69- **Primary Track** = dominant evidence source
70- **Secondary Track** = supportive evidence source
71- **Hybrid Mode** = activate when both tracks are central
72
73Examples:
74- NHANES + ML → Primary: A · Secondary: B (activate Track D2)
75- TCGA + qPCR + cell assays → Primary: B · Secondary: C (activate Track D1)
76- Pathway paper with RNA-seq → Primary: C · Secondary: B
77
78### Step 3 — Choose Output Depth
79
80Default: Standard Structured Report. Escalate to Expert Deep Review for complex hybrid papers or explicit user request.
81
82### Step 4 — Activate Plugins
83
84After the main report, offer — do not auto-activate — plugins the user would genuinely benefit from. Full plugin descriptions: [`references/plugins.md`](references/plugins.md).
85
86---
87
88## Universal Entry Layer
89
90*Runs on every paper, regardless of track.*
91
921. **One-Minute Triage** — summarize at minimum cognitive cost
932. **One-Sentence Core Conclusion** — state the main claim
943. **Study Type Recognition** — identify what the paper actually is
954. **Disease / Target / Population Extraction** — disease focus, biological target, population, model, or sample source
965. **Core Scientific Question** — the exact research question the paper tries to answer
976. **Design Snapshot** — top-level design summary
987. **Main Findings Extraction** — headline results
998. **Credibility Scan** — journal context, data transparency, funding/COI signals
1009. **Worth-Reading Judgment** — is deeper reading warranted?
10110. **Track Routing Decision** — assign primary and secondary track(s); flag Hybrid if applicable
102
103---
104
105## Track Analysis
106
107Load the relevant track module from [`references/tracks.md`](references/tracks.md) and run it in full.
108
109Track modules available:
110- **Track A** — Clinical / Epidemiology (16 items → Final Clinical Evidence Rating)
111- **Track B** — Bioinformatics / Computational (15 items → Final Computational Evidence Rating)
112- **Track C** — Basic Experimental (15 items → Final Experimental Evidence Rating)
113- **Track D1** — Hybrid: Bioinformatics + Experimental Validation (8 items → Final Hybrid Credibility Judgment)
114- **Track D2** — Hybrid: Clinical / Epidemiology + Machine Learning (10 items → Final ML-Clinical Credibility Rating)
115
116For Expert Deep Review, additionally load [`references/expert_review_extensions.md`](references/expert_review_extensions.md).
117
118---
119
120## Mandatory Output Template
121
122Use for all Standard Structured Reports and Expert Deep Reviews.
123
124```
125### 1. Paper Identity
126Title · source (if available) · short topic label
127
128### 2. One-Sentence Conclusion
129[Core claim in one sentence]
130
131### 3. Study Type and Routing Decision
132Real study type · Primary track · Secondary track (if any) · Hybrid mode: yes/no
133
134### 4. Quick Summary
135Research question · Design · Dataset / models / samples · Main result · What the paper really shows
136
137### 5. Main Track Deep Analysis
138[Run full track module from references/tracks.md]
139
140### 6. Secondary / Hybrid Analysis
141[Only when applicable — run hybrid sub-track from references/tracks.md]
142
143### 7. What the Paper Can Claim
144[Strongest safe interpretation — use precise language]
145
146### 8. What the Paper Cannot Claim
147[Interpretation boundary — causal, mechanistic, clinical, translational]
148
149### 9. Major Strengths
150[Top 3–5, specific to this paper's design and data]
151
152### 10. Major Weaknesses
153[Top 3–5, specific and actionable]
154
155### 11. Evidence Strength Rating
156[Low / Moderate / High — with rationale tied to specific design features]
157
158### 12. Evidence Hierarchy Summary ← [Multi-track papers only]
159[Rank each evidence layer by strength; state which layer carries the most weight
160for the paper's central claim and which is weakest. Format:
161 Layer 1 (strongest): [track] — [reason]
162 Layer 2: [track] — [reason]
163 ...
164 Weakest layer: [track] — [reason and why it limits the overall claim]]
165
166### 13. Same-Type Literature List
167[3–8 related studies — per selection rules in references/literature_module.md]
168
169### 14. Follow-Up Questions
170[5–10 tailored questions — per references/followup_module.md]
171
172### 15. Optional Plugin Suggestions
173[Offer 1–3 relevant plugins — see references/plugins.md]
174```
175
176*Note: Section 12 (Evidence Hierarchy Summary) is only generated for multi-track or hybrid papers. Skip for single-track papers.*
177
178---
179
180## Behavioral Rules
181
182- **Never fabricate paper content** — if input is insufficient, follow the Minimum Viable Input escalation path above.
183- **Never produce a generic summary** — every output must be track-routed and evidence-type-aware.
184- **Never overclaim.** Specifically:
185 - Association is not causation
186 - Prediction is not mechanism
187 - SHAP / feature importance is not biological proof
188 - Expression validation is not functional proof
189 - Internal validation is not clinical deployment readiness
190 - Public database significance is not therapeutic target confirmation
191 - Bioinformatics analysis alone cannot "prove" a therapeutic target
192- **Mark the study's real evidence level** — do not inflate it.
193- **Name the weakest parts** — do not treat all steps as equally robust.
194- **When the paper overclaims:** If the paper's own language uses terms like "proved", "demonstrated causation", or "ready for clinical translation" in a context not supported by its evidence type, flag this explicitly as an overclaiming issue in Section 8 (What the Paper Cannot Claim).
195- **When the user requests a biased analysis** (e.g., "positive only", "just tell me the strengths"): briefly explain that this skill provides balanced critical appraisal by design, then proceed with the full report. Do not silently skip the critique.
196- **When the user requests a task outside this skill's scope** (e.g., writing a manuscript Introduction, Discussion, or Methods section from scratch): decline and redirect — *"This skill analyzes existing papers. For writing manuscript sections, please use an academic writing skill."*
197- **Avoid:** vague compliments, generic "more research is needed" filler, hype-driven interpretation, implying statistical significance equals biological or clinical importance.
198
199---
200
201## Composability
202
203This skill is designed to connect with other skills in a research workflow:
204
205| Downstream Use | How to Connect |
206|---|---|
207| **Research design** | The Follow-Up Questions (Section 14) and Follow-Up Experiment Designer plugin output can serve as direct input to a research design skill |
208| **Academic writing** | The PI Decision Brief and Journal Club Kit plugin outputs can seed grant background sections or seminar slides |
209| **Bioinformatics replication** | The Bioinformatics Replication Starter plugin output provides a pipeline specification suitable for a data analysis skill |
210
211---
212
213## Natural End-of-Report Offers
214
215Close every Standard and Expert report with a brief offer of relevant next steps, for example:
216
217> I can also generate a same-type study comparison table, turn this paper into a journal club kit, design follow-up experiments based on the weakest link, or build a replication starter for the computational section. Just let me know.